Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Medtronic
Argus Health
Mallinckrodt
McKesson
Baxter
Boehringer Ingelheim
Queensland Health
Farmers Insurance

Generated: May 22, 2018

DrugPatentWatch Database Preview

TEGISON Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Tegison, and what generic alternatives are available?

Tegison is a drug marketed by Roche and is included in one NDA.

The generic ingredient in TEGISON is etretinate. Additional details are available on the etretinate profile page.
Summary for TEGISON
Drug patent expirations by year for TEGISON
Medical Subject Heading (MeSH) Categories for TEGISON
Synonyms for TEGISON
(2E,4E,6E,8E)-9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid ethyl ester
(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid ethyl ester
2,4,6,8-Nonanetetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, ethyl ester, all-trans-
2,4,6,8-Nonanetetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-,ethyl ester, all-trans-
2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-, ethyl ester, (all-E-)
2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, ethyl ester, (2E,4E,6E,8E)-
2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, ethyl ester, (all-E)-
2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, ethyl ester, (all-E)- (9CI)
2,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, ethyl ester, (all E)-
2,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, ethyl ester, (all-E)-
3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonanetetraenoic acid ethyl ester
350E480
42125-EP2311808A1
42125-EP2311829A1
54350-48-0
65M2UDR9AG
69427-41-4
A830117
AB01275503-01
AC-6823
AC1NQZZ1
AC1Q646U
AKOS015889992
AN-9659
B10-9359
BRD-K36248164-001-01-8
C23H30O3
CAS-54350-48-0
CCG-220590
CCRIS 3615
CHEBI:4913
CHEBI:94591
CHEMBL464
CS-3926
D00316
D0B1IP
DR001828
DSSTox_CID_3036
DSSTox_GSID_23036
DSSTox_RID_76843
DTXSID0023036
EINECS 259-119-3
ethyl (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoate
ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoate
ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
Ethyl (all-E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate
Ethyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate
ethyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
Ethyl all-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate
Ethyl etrinoate
etretinate
Etretinate (JAN/USAN/INN)
Etretinate [USAN:BAN:INN:JAN]
Etretinate [USAN:INN:BAN:JAN]
Etretinato
Etretinato [INN-Spanish]
Etretinatum
Etretinatum [INN-Latin]
GTPL7599
HMS2090G06
HQMNCQVAMBCHCO-DJRRULDNSA-N
HSDB 7185
HY-B0797
LMPR01090046
LP092129
LS-96864
MolPort-005-937-301
NCGC00167500-01
NCGC00167500-02
NSC 297936
NSC-297936
NSC297936
Retinoid
Ro 10-9359
Ro-10-9359
Ro-109359
Ro-13-7837
s4699
SC-18505
SCHEMBL3123
SR-05000001511
SR-05000001511-2
TEGISON (TN)
Tigason
tigasone
Tigazon
Tox21_112501
Tox21_112501_1
UNII-65M2UDR9AG
W-105640
ZINC3830820

US Patents and Regulatory Information for TEGISON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Roche TEGISON etretinate CAPSULE;ORAL 019369-001 Sep 30, 1986 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Roche TEGISON etretinate CAPSULE;ORAL 019369-002 Sep 30, 1986 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for TEGISON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Roche TEGISON etretinate CAPSULE;ORAL 019369-002 Sep 30, 1986 ➤ Sign Up ➤ Sign Up
Roche TEGISON etretinate CAPSULE;ORAL 019369-001 Sep 30, 1986 ➤ Sign Up ➤ Sign Up
Roche TEGISON etretinate CAPSULE;ORAL 019369-002 Sep 30, 1986 ➤ Sign Up ➤ Sign Up
Roche TEGISON etretinate CAPSULE;ORAL 019369-001 Sep 30, 1986 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
AstraZeneca
Moodys
Cantor Fitzgerald
Boehringer Ingelheim
US Army
Accenture
QuintilesIMS
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.